Beta Pharma

Beta Pharma

Pharmaceuticals, 5 Vaughn Dr, Princeton, New Jersey, 08540, United States, 11-50 Employees

betapharma.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 16*********

Who is BETA PHARMA

Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our produc...

Read More

map
  • 5 Vaughn Dr, Princeton, New Jersey, 08540, United States Headquarters: 5 Vaughn Dr, Princeton, New Jersey, 08540, United States
  • 1996 Date Founded: 1996
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 446110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from BETA PHARMA

Beta Pharma Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Beta Pharma

Answer: Beta Pharma's headquarters are located at 5 Vaughn Dr, Princeton, New Jersey, 08540, United States

Answer: Beta Pharma's phone number is 16*********

Answer: Beta Pharma's official website is https://betapharma.com

Answer: Beta Pharma's revenue is $10 Million to $25 Million

Answer: Beta Pharma's SIC: 2834

Answer: Beta Pharma's NAICS: 446110

Answer: Beta Pharma has 11-50 employees

Answer: Beta Pharma is in Pharmaceuticals

Answer: Beta Pharma contact info: Phone number: 16********* Website: https://betapharma.com

Answer: Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our products pipeline is diverse and undergoing rapid development. Beta Pharma Inc. was founded in 1996, at Science Park of Yale, as a contract research organization (named Beta Chemicals Inc.) to provide custom synthesis service for the pharmaceutical and biotechnology R&D community. In May of 2006, our novel EGFR inhibitor, Icotinib, entered into a Phase I clinical trial in China. The SFDA approved Icotinib on June 7, 2011. The global registration of Icotinib is undergoing, with our regional partners worldwide.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access